Butterfly Network (BFLY) Q4 2025: Embedded Revenue Jumps 76% on Midjourney AI Deal, Platform Ambitions Sharpen
Butterfly Network’s Q4 marked a pivotal inflection, with embedded platform revenue surging and the Midjourney AI partnership validating its shift from devices to platform enabler. The company’s transformation from a pure-play handheld ultrasound vendor to a semiconductor-powered digital imaging platform is now tangible in financials, execution, and pipeline. Investors face a new calculus: Butterfly’s future hinges on scaling Butterfly Embedded and realizing out-year upside from AI-native imaging use cases.
Summary
- Embedded Platform Validated: Midjourney partnership catalyzes Butterfly’s transition to a semiconductor-first, platform business.
- Core Ultrasound Franchise Holds: POCUS and enterprise pipeline momentum offset international softness, with AI-driven workflow enhancements gaining traction.
- Multi-Channel Growth Path: Home care pilots and expanding embedded partner pipeline position Butterfly for diversified revenue streams in 2026 and beyond.
Business Overview
Butterfly Network develops and commercializes semiconductor-based digital ultrasound technology. Its primary revenue streams are handheld point-of-care ultrasound (POCUS) devices, software and cloud services, and Butterfly Embedded, which licenses its ultrasound-on-chip platform to third parties. The business is structured around core device/software sales, enterprise SaaS imaging solutions, and emerging embedded partnerships—including AI and home care applications.
Performance Analysis
Q4 2025 delivered a step-change for Butterfly Network, with total revenue up 41% year-over-year to $31.5 million, marking the company’s highest quarterly result to date. This growth was driven by two distinct engines: the core POCUS segment, which grew 15% YoY, and a breakout in Butterfly Embedded revenue, largely from the Midjourney AI partnership. Notably, software and services revenue rose 76% YoY, now comprising 43% of total revenue, up from 34% a year ago—a clear sign of the business model’s shift toward platform economics.
Gross margin expanded to 67%, reflecting the higher mix of software and embedded revenue, along with lower amortization costs. Operating discipline was evident: adjusted EBITDA loss narrowed by 65% to $3.2 million. Butterfly also posted its first quarter of positive operating cash flow, aided by upfront payments from Midjourney. U.S. sales outperformed, with 44% unit growth and embedded revenue offsetting a 6% YoY international decline. The IQ3 device and Compass AI software drove higher average selling prices and improved enterprise pipeline conversion.
- Embedded Revenue Inflection: Butterfly Embedded, led by the Midjourney deal, accounted for a material portion of Q4 revenue and set up multi-year recurring revenue potential.
- Enterprise Pipeline Growth: Launch of Compass AI drove a 50%+ increase in enterprise pipeline, refreshing core accounts and attracting new hospital systems.
- Operating Leverage Emerges: Positive cash flow and improved EBITDA margin reflect a more scalable, disciplined operating model as the business pivots to platform economics.
While international sales lagged, management signaled renewed momentum in global health and NGO channels for 2026. The overall financial profile now reflects a business with less reliance on hardware and growing leverage from software and embedded partnerships.
Executive Commentary
"This deal is more than revenue, it is validation. It's a foundational step towards Butterfly's reinvention into a platform company."
Joseph DeVivo, Chairman and Chief Executive Officer
"Butterfly certainly navigated a few challenges in its early years as a public company. However, the company has made the necessary difficult adjustments, including improving its operating efficiency, choosing the markets it can win in, selecting the best ways to leverage its IP and technology advantage, and allocating its resources towards higher ROI opportunities and markets."
John Daugherty, Chief Financial Officer
Strategic Positioning
1. Embedded Platform Expansion
Butterfly Embedded, the company’s semiconductor ultrasound licensing platform, is now a core growth engine. The Midjourney AI partnership—a $74 million contract with milestone, licensing, and future revenue share components—showcases Butterfly’s ability to monetize its chip architecture beyond medical devices. Management confirmed a growing pipeline of 8-9 embedded partners, including both large tech and startup collaborators, with additional research-tier agreements expected in 2026.
2. Core POCUS Franchise and Enterprise SaaS
Point-of-care ultrasound (POCUS) remains foundational, with robust U.S. unit growth and the launch of Compass AI, a cloud-based workflow and documentation tool. Compass AI is driving deeper enterprise adoption by streamlining scan documentation and integrating with hospital systems, reducing workflow friction and boosting ROI for health systems.
3. Home Care and New Channels
The home care initiative is positioned as a future revenue catalyst, with the first commercial agreement expected by mid-2026. Management projects this channel could eventually surpass POCUS in revenue potential, as AI-enabled imaging empowers nurses and caregivers to conduct scans outside hospital settings, reducing readmissions and expanding Butterfly’s addressable market.
4. R&D and Chip Roadmap
Butterfly is accelerating its semiconductor innovation, with the fifth-generation P5.1 chip in production and Apollo, a next-gen architecture promising 20x data and compute performance, now in development. These advances underpin both the core device roadmap and the flexibility to serve diverse embedded use cases, from wearables to brain-computer interfaces.
5. Global and NGO Expansion
International growth remains a focus, with over 1,000 NGO partners and new market entries in South America, the Middle East, and Asia. Regulatory wins like GovRamp and pending FedRamp certifications are expected to unlock further U.S. government and global deployment opportunities in 2026.
Key Considerations
Butterfly’s Q4 2025 marks a clear pivot from medical device pure-play to platform business, with embedded revenue, software mix, and a robust chip roadmap as strategic levers. Investors must weigh execution risk in scaling Butterfly Embedded, the timing and magnitude of home care commercialization, and the durability of core POCUS growth amid industry competition.
Key Considerations:
- Embedded Revenue Visibility: Midjourney provides multi-year revenue, but future upside depends on successful commercialization and additional partner conversions.
- Enterprise SaaS Differentiation: Compass AI and workflow integration are deepening hospital penetration, but continued ease-of-use and ROI proof points will be critical to defend share.
- Home Care Ramp: The home channel could be transformative, but execution risk remains around pilot-to-scale transition and payer/provider adoption.
- Semiconductor Innovation Cycle: Success in chip R&D will determine Butterfly’s ability to stay ahead of analog competitors and serve new AI-driven use cases.
- International Turnaround: Renewed global health and NGO engagement could offset recent international softness, but macro and regulatory headwinds persist.
Risks
Execution risk is elevated as Butterfly shifts to a platform model, with embedded revenue still concentrated in early-stage partnerships. Tariff headwinds and international volatility could pressure margins and delay global expansion. The home care channel, while promising, is pre-commercial and may not ramp as quickly as forecast. Competitive threats from both legacy device makers and new AI entrants remain acute, particularly as digital imaging and workflow software become more crowded.
Forward Outlook
For Q1 2026, Butterfly guided to:
- Revenue of $24 million to $28 million, reflecting seasonal softness and Q4 outperformance pull-forward.
- Adjusted EBITDA loss of $8 million to $10 million, impacted by payroll tax resets and annual sales meeting costs.
For full-year 2026, management guided:
- Revenue of $117 million to $121 million, up 20% to 24% year-over-year.
- Adjusted EBITDA loss of $21 million to $25 million, including investments in embedded and R&D, and tariff impacts.
Management highlighted:
- Continued investment in core POCUS, SaaS, and Butterfly Embedded platform expansion.
- Home care commercialization in H2 2026, with material revenue impact expected in 2027.
Takeaways
- Platform Transition Realized: Butterfly’s embedded business is now a material contributor, validating the semiconductor-first strategy and opening new TAM.
- Core Franchise Resilient: POCUS and enterprise SaaS remain growth engines, with Compass AI and medical school channel expansion offsetting international drag.
- Future Upside Tied to Execution: Investors should watch for embedded partner pipeline conversion, home care ramp, and chip roadmap milestones as the next phase of growth unfolds.
Conclusion
Butterfly Network’s Q4 2025 results mark a decisive shift from device maker to digital imaging platform enabler, with embedded revenue, SaaS mix, and a robust innovation pipeline driving the next growth chapter. Execution on embedded partnerships and home care commercialization will define Butterfly’s ability to scale and defend its disruptive edge in 2026 and beyond.
Industry Read-Through
Butterfly’s embedded platform momentum signals a new era for digital imaging and AI-driven medical devices, with semiconductor-based architectures enabling new use cases beyond traditional hospital settings. Competitors in ultrasound, diagnostic imaging, and AI-enabled healthcare should note the rising importance of platform economics, workflow SaaS, and ecosystem partnerships. Early validation from AI partners like Midjourney suggests that proprietary chip technology and flexible APIs will be key differentiators as imaging moves into home care, wearables, and continuous monitoring. Tariff and regulatory volatility remain sector-wide risks, but the shift to software and embedded revenue streams offers a path to higher-margin, recurring business models across medtech and digital health.